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Abstract
Background: MicroRNAs (miRNAs) show differential expression across breast cancer subtypes and have both
oncogenic and tumor-suppressive roles. Numerous microarray studies reported different expression patterns of
miRNAs in breast cancers and found clinical interest for several miRNAs but often with contradictory results. Aim
of this study is to identify miRNAs that are differentially expressed in estrogen receptor positive (ER+) and negative
(ER−) breast primary tumors to better understand the molecular basis for the phenotypic differences between these
two sub-types of carcinomas and to find potential clinically relevant miRNAs.
Methods: We used the robust and reproductive tool of quantitative RT-PCR in a large cohort of well-annotated 153
breast cancers with long-term follow-up to identify miRNAs specifically differentially expressed between ER+ and ER−
breast cancers. Cytotoxicity tests and transfection experiments were then used to examine the role and the regulation
mechanisms of selected miRNAs.
Results: We identified a robust collection of 20 miRNAs significantly deregulated in ER+ compared to ER− breast
cancers : 12 up-regulated and eight down-regulated miRNAs. MiR-190b retained our attention as it was the miRNA the
most strongly over-expressed in ER+ compared to ER− with a fold change upper to 23. It was also significantly up-
regulated in ER+/Normal breast tissue and down-regulated in ER−/Normal breast tissue. Functional experiments showed
that miR-190b expression is not directly regulated by estradiol and that miR-190b does not affect breast cancer cell lines
proliferation. Expression level of miR-190b impacts metastasis-free and event-free survival independently of ER status.
Conclusions: This study reveals miR-190b as the highest up-regulated miRNA in hormone-dependent breast cancers.
Due to its specificity and high expression level, miR-190b could therefore represent a new biomarker in hormone-
dependent breast cancers but its exact role carcinogenesis remains to elucidate.
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Background
Breast cancer is the leading cause of cancer death in
women worldwide. Despite advances in the understand-
ing of cancer pathogenesis and improvement in diagno-
sis and treatment over the past few decades, biomarkers
of clinical interest are not so numerous. Now it is well
documented that endogenous estrogens known as an
important regulator of development, growth and differ-
entiation of the normal mammary gland play also a
major role in the development and progression of breast
cancer [1]. The mammary cell proliferation signals are
mediated in part by the estrogen receptor alpha (ER).
The expression of ER in breast tumors is frequently used
to separate breast cancer patients in a clinical setting
both as an important prognostic marker for prognosis
and in predicting the likelihood of response to endocrine
therapy. Although the majority of primary breast cancers
are ER-positive (ER+) and respond well to antiestrogen
therapy, up to one-third of patients with breast cancer
lack ER (ER−) at the time of diagnosis, and a fraction of
breast cancers that are initially ER+ lose ER expression
during tumor progression [2]. These patients fail to
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respond to antiestrogen therapy and have higher tumor
aggressiveness and poor prognosis. Previous studies have
shown that ER absence is a result of hypermethylation
of CpG islands in the 5’ region of ER coding gene
(ESR1) in a fraction of breast cancer [2]. However, the
molecular mechanism of the rest of the ER− breast cases
and the molecule(s) involving ER hypermethylation re-
main largely unknown. Other mechanisms involved in
altering ER expression have been identified, including mu-
tations within the open reading frame of ESR1 [3] as well
as ESR1 amplification increasing the ER protein expres-
sion [4]. Recently, ESR1 ligand-binding domain mutations
were described in hormone-resistant breast cancers [5].
Since their first description in C. Elegans in 1993, in-
creasing numbers of studies showing frequent deregula-
tion of microRNAs (miRNAs) in human breast cancers
and association of some of them with cancer metastasis
and poor prognosis suggesting an important role of miR-
NAs in cancer development and progression [6, 7]. miR-
NAs are small non-coding RNA gene products able to
regulate gene expression at the post-transcriptional level.
Thus, today, miRNAs are increasingly seen as important
regulators of gene expression in breast cancers, acting
either as oncogenes (such as miR-21) or tumor suppres-
sors (such as let-7), and affecting through different
mechanisms many cellular processes that are routinely
altered in cancer, such as differentiation, proliferation,
apoptosis, metastasis and telomere maintenance [8–11].
MiRNAs are also thought of as biomarkers in cancer
diagnosis and prognosis [12]. The diagnostic potential of
circulating miRNAs is based mainly on their non-
invasive detection in serum and plasma and on their
high resistance under difficult environmental conditions,
offering them therefore an emerging role in developing
new follow-up markers and strategies for cancer treat-
ment [13–15]. Moreover, studies suggested that expres-
sion profiles of miRNAs are informative for the
classification of human breast cancers [16–18]. Numer-
ous datas are available regarding the miRNA expression
in ER+ and ER− breast cancer tissues and come mainly
from studies using miRNA microarray techniques [16,
19, 20]. Results and conclusions from these old studies
are generally not consistent and sometimes even con-
flicting. More recently, miRNA landscape in breast can-
cer was deciphering in a large cohort with matching
detailed clinical annotation and long-term follow-up but
not particularly taking into account ER+ and ER− con-
texts [17]. Taken together, these finding have prompted
us to use the robust quantitative RT-PCR technology to
identify miRNAs that are differentially expressed in ER+
and ER− in breast primary tumors with the aim to better
understand the molecular basis for the phenotypic dif-
ferences between these two sub-types of carcinomas and
to find potential clinically relevant miRNAs.
Methods
Patients and samples
Breast tumor samples were obtained from 184 post-
menopausal women with primary unilateral non meta-
static breast adenocarcinoma who underwent biopsies
or initial surgery at the Curie Institute/René Huguenin
Hospital (Saint-Cloud, France) between 1984 and 2009.
Each patient signed a written informed consent form
and this study was approved by the Curie Institute/
René Huguenin Hospital ethics committee. Immediately
after biopsy or surgery, the tumor samples were stored
in liquid nitrogen in −80 °C until RNA extraction. All
samples analyzed contained more than 70 % of tumor
cells. Tumor samples included 106 ER+ and 78 ER− tu-
mors. ER status was determined at the protein level by
using biochemical methods (Dextran-coated charcoal
method until 1988 and enzyme immunoassay there-
after) and was confirmed at mRNA level by RT-PCR.
Control samples consisted of twelve specimens of nor-
mal breast tissue obtained from women undergoing
cosmetic breast surgery or adjacent normal breast tis-
sue from breast cancer patients [21]. Thirty-one of
breast tumor samples, comprising 21 ER+ and 10 ER−,
as well as 8 normal breast samples, were used as a RT-
PCR pan-miRNA screening set to identify and select
miRNAs differentially expressed in ER+ compared to
ER−. These selected miRNAs were then validated in the
remaining 153 breast tumor samples comprising 85 ER+
and 68 ER− compared to eight normal breast samples.
Clinicopathological characteristics of patients in relation
to metastatic free survival in the screening and validation
series are provided in Table 1. In the screening set, we vol-
untary included more SBR grade III tumors with the aim
to facilitate identification of robust genes differentially
expressed whereas the validation set is totally representa-
tive of breast cancers treated in the Curie institute/René
huguenin hospital between 1984 and 2009.
RNA extraction
Total RNA was extracted from breast tissue by using the
acid-phenol guanidium method. Total RNA concentra-
tion was quantified using a NanoDrop™ spectrophotom-
eter. RNA quality was determined by agarose gel
electrophoresis and ethidium bromide staining. The 18S
and 28S RNA bands were visualized under ultraviolet
light.
miRNA expression profiling
MiRNA expression levels in samples were quantified by
quantitative RT-PCR (RT-qPCR) using the SYBR Green
Master Mix kit on the ABI Prism 7900 Sequence Detec-
tion System (Perkin-Elmer Applied Biosystems, Foster
City, CA, USA). The Human miScript Primer Assays
version 9.0 and 11.0 from Qiagen, designed to detect
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804 human miRNA probes, were used according to the
manufacturer’s guidelines. Small nucleolar RNA RNU44
(Qiagen) was used as endogenous control to normalize
miRNA expression levels. The relative expression level
of each miRNA, expressed as N-fold difference in target
miRNA expression relative toRNU44, and termed "Ntarget",
was calculated as follows: Ntarget = 2ΔCtsample. The value of
the cycle threshold (ΔCt) of a given sample was determined
by subtracting the Ct value of the target miRNA from
the average Ct value of RNU44. The Ntarget values of
samples were subsequently normalized such that the
median Ntarget value of normal breast samples was
one. To overcome limits of detection of RT-qPCR, and
be sure in expression values of miRNAs, we have con-
sidered a miRNA as relevant when the Ct values were
lower than 30 in at least 50 % of all samples analyzed.
Table 1 Pathological and clinical characteristics of patients in relation to metastasis free survival (MFS) in the screening and validation sets
Screening set (n = 31) Validation set (n = 153)
Characteristic Number of patients Number of
events (%)




≤65 years 17 3 (18) 67 33 (49)
>65 years 14 3 (21) 86 27 (31)
SBR histological gradeb,c 0.0453 0.0008
I + II 11 0 (0) 96 31 (32)
III 19 6 (32) 54 27 (50)
Lymph node statusc 0.6825 0.6493
Negative 9 2 (22) 33 11 (33)
Positive 21 3 (14) 112 47 (42)
Lymph node status 0.3521 0.0005
0 9 2 (22) 33 11 (33)
[1–3] 18 2 (11) 83 27 (33)
>3 3 1 (33) 29 20 (69)
Macroscopic tumor sizec 0.4955 0.0267
≤25 mm 20 3 (15) 61 18 (30)
>25 mm 11 3 (27) 83 40 (48)
Macroscopic tumor sizec 0.9925 0.1375
≤30 mm 26 5 (19) 92 34 (37)
>30 mm 5 1 (20) 52 24 (46)
Estrogen receptor statusc 0.2867 0.0005
Negative 10 1 (10) 68 34 (50)
Positive 21 5 (24) 85 26 (31)
Progesterone receptor statusc 0.2136 0.0005
Negative 11 1 (9) 68 34 (50)
Positive 20 5 (25) 85 26 (31)
HER2 statusc 0.8493 0.0595
Negative 22 5 (23) 111 41 (37)
Positive 5 1 (20) 42 19 (45)
Treatmentc 0.6248 0.0393
No treatment 4 0 (0) 13 8 (62)
Chemotherapy 1 0 (0) 32 14 (44)
Hormone therapy 21 5 (24) 93 31 (33)
Chemotherapy and hormone therapy 1 0 (0) 9 6 (67)
aLog-rank test
bScarff Bloom Richardson classification
cHistological or treatment information were not available for all tumors
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The relative expression of each miRNA was character-
ized by the median and the range, and a non-
parametric Mann–Whitney test was used for statistical
analysis of differences in miRNA expression between
groups.
Gene expression profiling
In the validation series, mRNA expression levels of Dicer
(NM_177438), Drosha (NM_013235), AGO2 (NM_012154),
DGCR8 (NM_022720), four protein-coding genes re-
quired to the miRNA biogenesis, and six host genes
CTDSPL (NM_005808.2), EVL (NM_016337.2), NFYC
(NM_014223.4) OGFRL1 (NM_024576.3), CTDSP1
(NM_021198.1), PTMA (NM_002823.4) containing the
identified miRNAs were measured by RT-qPCR.
Primers and PCR conditions are available on request,
and the RT-qPCR protocol is described above. The
mRNA expression level of each protein-coding gene is
relative to the TBP gene (NM_003194).
Breast cancer cell lines
Expression levels of selected miRNAs were measured by
RT-qPCR in a collection of RNAs from 30 human breast
cancer cell lines commonly used including 19 ER− (BT-20,
BT-549, HCC-38, HCC-70, HCC-202, HCC-1143, HCC-
1187, HCC-1569, HCC-1599, HCC-1937, HCC-1954, Hs-
578 T, MDA-MB-157, MDA-MB-231, MDA-MB-435 s,
MDA-MB-436, MDA-MB-453, MDA-MB-468 and SK-
BR-3) and 11 ER+ (BT-474, BT-483, CAMA1, HCC-1428,
HCC-1500, MCF-7, MDA-MB-134VI, MDA-MB-361,
MDA-MB-415, T-47D and ZR-75-1). These RNAs were
provided by the transfer department of Curie Institute.
For each miRNA and each cell line, mRNA levels were
normalized such that the median value of the ER− breast
cancer cell lines was one.
The effects of 17β-estradiol (E2) on the miRNA ex-
pression were studied on two ERα-positive breast cancer
cell lines whose growth is known to be stimulated by E2 :
MCF-7 cell line for all selected miRNAs and T-47D cell
line for miR-190b. They were cultured in either minimum
essential medium (MEM) or Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10 % fetal calf/
bovine serum and antibiotics (penicillin 50 g/ml,
streptomycin 50 g/ml and neomycin 100 g/ml) at 37 °C
with 5 % CO2. For experiments using E2, MCF-7 and
T-47D were grown in phenol red-free minimum essen-
tial medium (MEM) supplemented with 5 % charcoal-
dextran-stripped fetal calf serum for at least 3 days
before treatment. The cells were then treated with E2
(Sigma) diluted in ethanol (EtOH) at 1 nM for MCF-7
and 10 nM for T-47D, or with vehicle EtOH (control
cells). RNAs were extracted from these cells after 6 h,
18 h and 4 days of the presence of E2 and the mRNA
levels measured by RT-PCR were normalized such that
the median value of control cells was of one. Three in-
dependent experiments were realized for each time and
each condition. To verify the effects of E2 on growth of
cells, mRNA expression of pS2/TFF1 (NM_003225), a
well-known ERα-induced gene, was also measured by
RT-qPCR on the treated cells.
The effects of miR-190b expression on cellular prolif-
eration were studied on breast cancer cell lines ER+
MCF-7 and T-47D that were transfected with antagomir
against miR-190b (sequence complementary to miR-
190b which blocks its effect) and on breast cancer cell
line ER− MD-MBA-231 that was transfected with a miR-
190b mimic (double-stranded RNA which mimics
mature endogenous miR-190b) using a 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
proliferation assay. In brief, after transient transfection of
cells for 24 h with 40 nM of antagomir against miR-190b
or mimic of miR-190b (synthetized by Qiagen), the cells
were growth in normal medium for 48, 72 or 120 h to be
then treated with 0.5 mg/ml of the MTT labeling reagent
at 37 °C for 1 to 3 h and lysed in 150 μl of dimethyl sulfox-
ide at room temperature for 30 min. The cell viability was
thus determined by reading the absorbance at 450 to
570 nm of signal generated by MTT reduction which is
directly proportional to the cell number. For each cell line,
the data were collected from three independent experi-
ments and compared to the control group obtained by
transfection of non-targeting siRNA as negative control in
miRNA inhibition experiments or miRNA inhibitor as
negative control in miRNA mimic experiment.
Survival analysis
Metastasis-free survival (MFS) was determined as the
interval between initial diagnosis and detection of the
first metastasis. Survival distributions were estimated by
the Kaplan-Meier method, and the significance of differ-
ences between survival rates was ascertained with the
log-rank test. The Cox proportional hazards regression
model was used to assess prognostic significance, and
the results are presented as hazard ratios and 95 % con-
fidence intervals (CIs). Statistical analyses were per-
formed using GraphPad Prism 5 software.
Results
Differential miRNA expression between ER+ and ER− breast
tumors
To identify miRNA expression profiles in breast cancer
according to ER status, expression levels of 804 miRNAs
were measured by RT-qPCR technology in a well-
defined series of 21 ER+ and 10 ER− breast tumors and
in 8 normal breast tissues (Additional file 1: Table S1).
MiRNAs with high Ct values in this screening set and
miRNAs with very low expression levels (indicated by an
asterisk after their name) were not more studied,
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resulting in a list of 333 informative miRNAs (Additional
file 2: Table S2).
Among these 333 miRNAs a Mann–Whitney test
identified 155 miRNAs that were significantly differ-
ently expressed in ER+ compared to ER− tumors with a
p-value < 0.05 : 15 miRNAs were up-regulated and 140
miRNAs were down-regulated. We then selected miR-
NAs that were the most strongly deregulated and for
which the specificity of RT-qPCR amplification was
verified on the dissociation curve for RT-qPCR valid-
ation in a larger independent series of breast tumors.
Thus, we focused our study on 11 miRNAs for which
the expression level was increased by 2-fold in ER+
compared to ER− tumors and 7 miRNAs for which the
expression level was decreased by 4-fold in ER+ com-
pared to ER−tumors (Table 2).
miRNAs associated with ER status in an independent
validation series
The expression levels of these 18 miRNAs selected in
the screening series were then verified in a validation
series including 153 breast tumors (85 ER+ and 68 ER−)
and eight normal breast tissues (Table 3).
In these validation series, we also measured the ex-
pression levels of 12 miRNAs reported by the literature
to be particularly deregulated in ER+ breast tumors : let-
7a and let-7b [22, 23], miR-18a and miR-18b [24], miR-
21 [25], miR-22 [26], miR-155 [27, 28], miR-206 [29] and
mir-221 and 222 [30] as well as miR-19a and miR-92a1,
which, with miR-18a, belonged to the miR-17-92 cluster
[31] (Table 3).
Among the 11 up-regulated miRNAs selected from the
screening series, except miR-451, we validated the up-
regulation of miR-190b, miR-101-1, miR-193b, miR-342-
5p, miR-376c, miR-143, miR-30c2, miR-30e, miR-26a1
and miR-26b in ER+ compared to ER− (Table 3). Among
the 12 miRNAs selected from the literature, we found 2
other miRNAs up-regulated in ER+ compared to ER−:
let-7a1 and let-7b. However among these 12 up-
regulated miRNAs, we identified 5 different expression
profiles according to their expression in ER+/Normal and
ER−/Normal. Eight miRNAs (miR-26a1, miR-101-1, let-7b,
miR-30c2, miR-143, miR-26b, miR-376c and let-7a1)
showed a significant decrease of their expression in both
ER+ and in ER− compared to normal breast tissue (see
miR-26a1 for example in Additional file 3: Figure S1A)




tissue (n = 8)
ER+ breast
tumors (n = 21)
ER− breast
tumors (n = 10)
ER+/ER−
FC p-value
11 miRNAs up-regulated in ER+ compared to ER− with a FC > 2
miR-190b 1.0 (0.06-3.33) 14.5 (2.41-51.7) 0.46 (0.07-6.33) 31.26 <0.0001
miR-101-1 1.0 (0.00-2.21) 0.40 (0.05-1.23) 0.08 (0.01-0.48) 4.94 0.0033
miR-193b 1.0 (0.12-2.65) 1.87 (0.20-8.68) 0.48 (0.24-2.37) 3.89 0.0106
miR-342-5p 1.0 (0.63-1.74) 2.61 (0.30-7.37) 0.94 (0.32-2.87) 2.77 0.0296
miR-376c 1.0 (0.00-3.40) 0.53 (0.19-1.40) 0.20 (0.01-0.59) 2.60 0.0083
miR-451 1.0 (0.01-3.47) 0.15 (0.04-1.78) 0.06 (0.00-0.19) 2.55 0.0019
miR-143 1.0 (0.01-2.24) 0.26 (0.10-1.11) 0.10 (0.01-0.35) 2.52 0.0094
miR-30c2 1.0 (0.04-8.70) 1.99 (0.15-11.3) 0.87 (0.07-3.41) 2.29 0.0329
miR-30e 1.0 (0.11-9.13) 3.02 (0.29-13.6) 1.41 (0.08-5.73) 2.15 0.0405
miR-26a1 1.0 (0.09-2.57) 0.59 (0.28-3.86) 0.28 (0.08-0.86) 2.10 0.0014
miR-26b 1.0 (0.08-2.57) 0.52 (0.21-2.79) 0.25 (0.04-0.66) 2.10 0.0050
7 miRNAs down-regulated in ER+ compared to ER− with a FC > 4
miR-654-3p 1.0 (0.15-4.36) 0.58 (0.10-4.89) 4.25 (0.68-41.6) −7.29 0.0008
miR-203 1.0 (0.16-3.97) 1.54 (0.12-48.9) 8.86 (1.30-36.4) −5.76 0.0073
miR-146a 1.0 (0.07-2.95) 0.70 (0.07-4.48) 3.71 (0.27-15.3) −5.30 0.0106
miR-494 1.0 (0.24-3.18) 0.20 (0.03-1.68) 0.99 (0.11-1.86) −4.97 0.0191
miR-338-5p 1.0 (0.51-5.60) 0.40 (0.19-1.07) 1.92 (0.67-3.41) −4.82 <0.0001
miR-891a 1.0 (0.24-2.43) 0.34 (0.17-1.28) 1.63 (0.28-2.81) −4.77 0.0025
miR-1244 1.0 (0.22-3.30) 1.12 (0.09-2.79) 4.86 (0.76-17.5) −4.33 0.0050
Results in ER+ and ER− tumors are expressed as the median (range) of miRNA level relative to normal breast tissues and the difference in miRNA expression
between ER+ and ER− were analysed for significance with the Mann–Whitney test. The miRNAs are ranked according to the fold change (FC) calculated between
ER+ and ER−
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but with a significantly greater decrease in ER−/Normal
than in ER+/Normal (FC ranging from 2.1 to 11.1 and
from 1.7 to 7.1, respectively) (Table 4). The down-
regulation of miR-30e was specific to ER− (Additional
file 3: Figure S1B) since its expression was not differen-
tially expressed in ER+/Normal but significantly under-
expressed in ER−/Normal. MiR-193b did not particularly
retain our attention to the extent that this miRNA was
deregulated neither in ER+/Normal nor in ER−/Normal
(Additional file 3: Figure S1C). MiR-342-5p was signifi-
cantly up-regulated in ER+/Normal but not differentially
expressed in ER−/Normal (Additional file 3: Figure S1D),
revealing a specific up-regulation of miR-342-5p in ER+.
Finally, miR-190b retained our attention as it was the
miRNA the most strongly over-expressed in ER+ com-
pared to ER− with a FC upper to 23, much higher than FC
of other up-regulated miRNAs (Table 3, Additional file 3:
Figure S1E). Moreover the ER+ breast tumors showed a




breast tissue (n = 8)
ER+ breast
tumors (n = 85)
ER−breast
tumors (n = 68)
ER+/ER−
FC p-value
11 up-regulated miRNAs selected in the screening series
miR-190b 1.0 (0.32-1.57) 6.34 (0.71-32.3) 0.27 (0.02-6.23) 23.30 <0.0001
miR-101-1 1.0 (0.69-8.05) 0.30 (0.05-2.10) 0.15 (0.01-0.92) 2.01 <0.0001
miR-193b 1.0 (0.43-1.79) 1.44 (0.10-9.17) 1.00 (0.11-4.45) 1.43 0.0191
miR-342-5p 1.0 (0.78-2.16) 2.03 (0.29-19.4) 0.93 (0.10-3.65) 2.18 <0.0001
miR-376c 1.0 (0.52-3.04) 0.14 (0.02-1.55) 0.10 (0.02-0.83) 1.43 0.0064
miR-451 1.0 (0.32-11.1) 0.17 (0.02-14.0) 0.14 (0.01-9.77) 1.23 ns
miR-143 1.0 (0.45-2.72) 0.21 (0.03-1.40) 0.14 (0.02-0.74) 1.52 0.0140
miR-30c2 1.0 (0.69-1.72) 0.54 (0.12-3.06) 0.34 (0.09-1.17) 1.60 <0.0001
miR-30e 1.0 (0.70-2.98) 0.79 (0.12-4.57) 0.47 (0.10-2.28) 1.68 <0.0001
miR-26a1 1.0 (0.77-4.06) 0.34 (0.11-1.78) 0.09 (0.02-0.47) 3.64 <0.0001
miR-26b 1.0 (0.68-4.38) 0.49 (0.15-2.93) 0.34 (0.06-1.64) 1.44 0.0008
7 down-regulated miRNAs selected in the screening series
miR-654-3p 1.0 (0.72-1.34) 0.30 (0.05-2.68) 0.66 (0.04-17.8) −2.16 <0.0001
miR-203 1.0 (0.51-2.43) 0.88 (0.02-5.78) 1.51 (0.05-19.6) −1.72 0.0059
miR-146a 1.0 (0.54-3.71) 0.70 (0.07-3.63) 0.95 (0.10-4.30) −1.36 0.0344
miR-494 1.0 (0.85-2.17) 0.65 (0.02-6.96) 0.69 (0.02-9.03) −1.07 ns
miR-338-5p 1.0 (0.79-1.78) 0.84 (0.19-4.66) 0.96 (0.12-5.08) −1.15 ns
miR-891a 1.0 (0.77-1.64) 1.37 (0.14-8.43) 2.07 (0.37-15.5) −1.51 ns
miR-1244 1.0 (0.73-1.69) 1.23 (0.16-5.11) 2.34 (0.35-25.3) −1.91 <0.0001
12 miRNAs selected from the literature
let-7a 1.0 (0.73-1.79) 0.58 (0.15-2.00) 0.47 (0.11-2.99) 1.24 0.0055
let-7b 1.0 (0.71-1.69) 0.53 (0.08-2.04) 0.31 (0.04-0.82) 1.75 <0.0001
miR-18a 1.0 (0.49-3.33) 0.50 (0.06-2.53) 1.12 (0.12-23.9) −2.24 <0.0001
miR-18b 1.0 (0.47-4.45) 0.50 (0.07-3.52) 1.04 (0.13-25.3) −2.07 <0.0001
miR-19a 1.0 (0.70-2.13) 0.34 (0.03-2.61) 0.42 (0.02-14.4) −1.24 ns
miR-21 1.0 (0.49-5.26) 2.05 (0.41-16.6) 1.84 (0.21-9.53) 1.12 ns
miR-22 1.0 (0.38-4.51) 0.71 (0.12-12.9) 0.66 (0.09-3.36) 1.08 ns
miR-92a1 1.0 (0.68-1.40) 0.32 (0.10-1.17) 0.49 (0.09-8.95) −1.54 <0.0001
miR-155 1.0 (0.55-4.24) 2.06 (0.52-10.9) 3.97 (0.35-32.0) −1.93 <0.0001
miR-206 1.0 (0.01-2.28) 0.25 (0.02-7.71) 0.32 (0.01-2.74) −1.29 ns
miR-221 1.0 (0.65-1.92) 0.40 (0.07-4.24) 0.53 (0.05-5.55) −1.31 ns
miR-222 1.0 (0.63-2.30) 0.39 (0.06-2.68) 0.50 (0.04-3.88) −1.28 ns
Results in ER+ and ER− tumors are expressed as the median (range) of miRNA level relative to normal breast tissues. For each miRNA, we report the fold-change
(FC) between ER+ and ER− tumors and the p-value associated to Mann–Whitney test (ns for not significant)
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miR-190b up-regulation compared to normal breast tissue
with a FC of 6.34 whereas the ER− breast tumors, a down-
regulation with a FC of −3.70 (Table 4).
Among the seven down-regulated miRNAs selected
from the screening series, under-expression of four miR-
NAs, miR-654-3p, miR-203, miR-146a and miR-1244, in
ER+ compared to ER− was confirmed in the validation
series (Table 3). Among the miRNAs selected from the
literature, we found four other miRNAs down-regulated
in ER+ compared to ER−: miR-18a, miR-18b, miR-92a1
and miR-155. Among these eight down-regulated miR-
NAs, we identified five different expression profiles accord-
ing to their expression in ER+/Normal and RE−/Normal
(Additional file 4 and Table 4). The first profile concerned
miR-18a, miR-18b and miR-654-3p (see miR-654-3p for
example in Additional file 4: Figure S2A) that were not











FC p-value FC p-value
12 miRNAs up-regulated in ER+ compared to ER−
miR-190b 1.0 (0.32-1.57) 6.34 (0.71-32.3) 6.34 <0.0001 0.27 (0.02-6.23) −3.70 0.0284
miR-26a1 1.0 (0.77-4.06) 0.34 (0.11-1.78) −2.94 <0.0001 0.09 (0.02-0.47) −11.11 <0.0001
miR-342-5p 1.0 (0.78-2.16) 2.03 (0.29-19.4) 2.03 0.0026 0.93 (0.10-3.65) −1.07 ns
miR-101-1 1.0 (0.69-8.05) 0.30 (0.05-2.10) −3.33 <0.0001 0.15 (0.01-0.92) −6.67 <0.0001
let-7b 1.0 (0.71-1.69) 0.53 (0.08-2.04) −1.89 0.0007 0.31 (0.04-0.82) −3.23 <0.0001
miR-30e 1.0 (0.70-2.98) 0.79 (0.12-4.57) −1.27 ns 0.47 (0.10-2.28) −2.13 0.0005
miR-30c2 1.0 (0.69-1.72) 0.54 (0.12-3.06) −1.85 0.0032 0.34 (0.09-1.17) −2.94 <0.0001
miR-143 1.0 (0.45-2.72) 0.21 (0.03-1.40) −4.76 <0.0001 0.14 (0.02-0.74) −7.14 <0.0001
miR-26b 1.0 (0.68-4.38) 0.49 (0.15-2.93) −2.04 0.0034 0.34 (0.06-1.64) −2.94 0.0001
miR-376c 1.0 (0.52-3.04) 0.14 (0.02-1.55) −7.14 <0.0001 0.10 (0.02-0.83) −10.00 <0.0001
miR-193b 1.0 (0.43-1.79) 1.44 (0.10-9,17) 1.44 ns 1.00 (0.11-4.45) 1.00 ns
let-7a 1.0 (0.73-1.79) 0.58 (0.15-2.00) −1.72 0.0017 0.47 (0.11-2.99) −2.13 0.0002
8 miRNAs down-regulated in ER+ compared to ER−
miR-18a 1.0 (0.49-3.33) 0.50 (0.06-2.53) −2.00 0.0074 1.12 (0.12-23.9) 1.12 ns
miR-654-3p 1.0 (0.72-1.34) 0.30 (0.05-2.68) −3.33 0.0001 0.66 (0.04-17.8) −1.51 ns
miR-18b 1.0 (0.47-4.45) 0.50 (0.07-3.52) −2.00 0.0063 1.04 (0.13-25.3) 1.04 ns
miR-155 1.0 (0.55-4.24) 2.06 (0.52-10.9) 2.06 0.0181 3.97 (0.35-32.0) 3.97 0.0019
miR-1244 1.0 (0.73-1.69) 1.23 (0.16-5.11) 1.23 ns 2.34 (0.35-25.3) 2.34 0.0073
miR-203 1.0 (0.51-2.43) 0.88 (0.02-5.78) −1.14 ns 1.51 (0.05-19.6) 1.51 ns
miR-92a1 1.0 (0.68-1.40) 0.32 (0.10-1.17) −3.12 <0.0001 0.49 (0.09-8.95) −2.04 0.0007
miR-146a 1.0 (0.54-3.71) 0.70 (0.07-3.63) −1.43 ns 0.95 (0.10-4.25) −1.05 ns
10 miRNAs not differentially expressed in ER+ compared to ER−
miR-451 1.0 (0.32-11.1) 0.17 (0.02-14.0) −5.88 0.0009 0.14 (0.01-9.77) −7.14 0.0003
miR-21 1.0 (0.49-5.26) 2.05 (0.41-16.6) 2.05 0.0269 1.84 (0.21-9.53) 1.84 ns
miR-22 1.0 (0.38-4.51) 0.71 (0.12-12.9) −1.41 ns 0.66 (0.09-3.36) −1.51 ns
miR-494 1.0 (0.85-2.17) 0.65 (0.02-6.96) −1.54 0.0462 0.69 (0.02-9.03) −1.45 0.0449
miR-338-5p 1.0 (0.79-1.78) 0.84 (0.19-4.66) −1.19 ns 0.96 (0.12-5.08) −1.04 ns
miR-19a 1.0 (0.70-2.13) 0.34 (0.03-2.61) −2.94 0.0003 0.42 (0.02-14.4) −2.38 0.0037
miR-222 1.0 (0.63-2.30) 0.39 (0.06-2.68) −2.56 0.0001 0.50 (0.04-3.88) −2.00 0.0015
miR-206 1.0 (0.01-2.28) 0.25 (0.02-7.71) −4.00 0.0156 0.32 (0.01-2.74) −3.12 0.0114
miR-221 1.0 (0.65-1.92) 0.40 (0.07-4.24) −2.50 0.0004 0.53 (0.05-5.55) −1.89 0.0098
miR-891a 1.0 (0.77-1.64) 1.37 (0.14-8.43) 1.37 ns 2.07 (0.37-15.5) 2.07 0.0381
Results in ER+ and ER− breast tumors are expressed as the median (range) of miRNA level relative to normal breast tissues. For each miRNA, we report the fold-
change (FC) between ER+ or ER− breast tumors and normal breast tissue and the p-value associated to Mann-Whitney’s test (ns for not significant)
Cizeron-Clairac et al. BMC Cancer  (2015) 15:499 Page 7 of 14
differentially expressed in ER−/Normal but significantly
under-expressed in ER+/Normal, revealing a specific
down-regulation of miR-18a, miR-18b and miR-654-3p in
ER+ (Table 4). We found two miRNAs that were not differ-
entially expressed in breast cancer, miR-203 and miR-146a
(see miR-146a for example in Additional file 4: Figure S2B)
and one miRNA, miR-92a1, that was significantly down-
regulated in breast cancer (Additional file 4: Figure S2C).
The two last expression profiles concerned miR-155
(Additional file 4: Figure S2D) and miR-1244 (Additional
file 4: Figure S2E). Although these two miRNAs were sig-
nificantly up-regulated in ER− breast cancer compared to
normal breast tissue, miR-155 showed also significant in-
crease of its expression in ER+/Normal whereas miR-1244
was not differentially expressed in ER+/Normal, revealing
a specific up-regulation of miR-1244 in ER− (Table 4).
Expression of genes required for miRNAs biogenesis in ER+
and ER− breast tumors
The majority of these 20 miRNAs deregulated in ER+
breast tumors, except miR-155 and miR-1244, were sig-
nificantly down-regulated in breast cancers compared to
normal breast tissue (Additional file 5: Table S3) so we
explored if genes required for miRNAs biogenesis could
be deregulated. In the validation series, we measured by
RT-qPCR the expression levels of DICER1, DROSHA,
AGO2 and DGCR8, four genes encoding proteins playing
pivotal roles in the processing of mature miRNAs. We
found that these genes were deregulated in ER+ com-
pared to ER− breast tumors: DICER1, DROSHA and
DGCR8 were significantly under-expressed in ER− while
AGO2 was moderate over-expressed in ER−. We did
not however observe significant expression changes in
ER+/Normal for these four genes. On the other hand,
we observed a significant under-expression of DICER1
in ER−/Normal (Table 5). These results revealed a de-
regulation of genes required for miRNA biogenesis in
the absence of ER.
Expression of host genes of miRNAs in ER+ and ER−
breast tumors
Among the 20 miRNAs identified as deregulated in ER+
compared to ER− breast tumors, 6 miRNAs are located
in intragenic regions: miR-26a1 in CTDSPL, miR-342-5p
in EVL, miR-30e in NFYC, miR-30c2 in OGFRL1, miR-
26b in CTDSP1 and miR-1244 in PTMA. The expression
levels of these 6 host genes were then measured, by RT-
qPCR, in the validation series (Table 6). These genes
showed significant expression difference between ER+
and ER−similar to their miRNA (Table 4). Thus
CTDSPL, EVL, NFYC, OGFRL1 and CTDSP1 are more
expressed in ER+ than in ER− like miR-26a1, miR-342-
5p, miR-30a, miR-30c2 and miR-26b respectively, and
PTMAP2 is less expressed in ER+ than in ER− like miR-
1244. Moreover Spearman’s rank correlation analysis re-
vealed a significant and positive correlation between ex-
pression of all host genes and its resident miRNA in breast
tumors : miR-26a1 and CDTSPL (r = 0.3157, p < 0.0001),
miR-342-5p and EVL (r = 0.5931, p < 0.0001), miR-30e and
NFYC (r = 0.3157, p < 0.0001), miR-30c2 and OGFRL1
(r = .02803, p= 0.0004), miR-26b and CDTSP1 (r = 0.2502,
p= 0.0018) and miR-1244 and PTMA (r = 0.2258, p= 0.005),
indicating a miRNA-host co-transcription. According to ER
status, a significant correlation was observed for miR-342-
5p/EVL in ER+ (r = 0.3817, p = 0.0004) and for miR-26b/
CTDSP1 and miR-1244/PTMAP2 in ER− (r = 0.3584, p =
0.0029 and r = 0.2822, p = 0.0197, respectively) (data not
shown).
miRNA expression in human breast cancer cell lines
We further evaluated the expression levels of 20 miRNAs
identified as deregulated in ER+ compared to ER− breast
tumors in 30 human breast cancer cell lines including 19
ER− and 11 ER+. The patterns of expression changes ob-
served between ER+ and ER− breast tumors do not have
been validated in breast cancer cell lines for all miRNAs
(Table 7). We only confirmed the significant over-
Table 5 Expression levels of 4 genes required for miRNA biogenesis in breast tissues
Breast tissue ER+/ER− ER+/Normal ER−/Normal
Gene Normal (n = 8) ER+ (n = 85) ER− (n = 68) FC p-value FC p-value FC p-value
DICER1 1.0 0.92 0.50 1.85 <0.0001 −1.09 ns −2.00 0.0004
(0.79-1.36) (0.05-3.18) (0.10-1.94)
DROSHA 1.0 1.27 0.77 1.65 <0.0001 1.27 ns −1.30 0.0486
(0.77-1.56) (0.08-4.91) (0.09-6.37)
DGCR8 1.0 1.05 0.72 1.46 <0.0001 1.05 ns −1.39 0.0506
(0.78-1.56) (0.19-4.77) (0.13-3.44)
AGO2 1.0 0.80 1.10 −1.37 0.0433 −1.25 ns 1.10 ns
(0.56-1.10) (0.17-3.74) (0.08-4.74)
Results in ER+ and ER− breast tumors are expressed as the median (range) of level relative to normal breast tissues. For each comparison, we report the fold-change (FC)
and the p-value associated to Mann-Whitney’s test (ns for not significant)
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Table 6 Expression levels of host genes containing miRNAs deregulated in ER+ compared to ER− breast tumors in the validation
series
Breast tissue ER+/ER−
miRNA Host gene Normal (n = 8) ER+ (n = 85) ER− (n = 68) FC p-value
miR-26a1 CTDSPL 1.0 0.95 0.42 2.26 <0.0001
(0.49-2.20) (0.21-19.6) (0.03-7.64)
miR-342-5p EVL 1.0 3.36 0.54 6.17 <0.0001
(0.89-1.42) (0.16-26.9) (0.08-2.77)
miR-30e NFYC 1.0 1.00 0.90 1.11 0.0143
(0.85-1.42) (0.06-2.91) (0.45-2.46)
miR-30c2 OGFRL1 1.0 0.67 0.44 1.51 0.0002
(0.69-1.29) (0.03-2.20) (0.08-2.04)
miR-26b CTDSP1 1.0 0.93 0.67 1.39 <0.0001
(0.66-1.56) (0.20-3.85) (0.25-3.11)
miR-1244 PTMAP2 1.0 1.41 1.89 −1.34 0.0002
(0.53-2.04) (0.00-6.10) (0.85-12.4)
Results in ER+ and ER− breast tumors are expressed as the median (range) of level relative to normal breast tissues. For each comparison, we report the fold-change (FC)
and the p-value associated to Mann-Whitney’s test (ns for not significant)
Table 7 Relative miRNA expression levels of 20 miRNAs in breast cancer cell lines. Results in breast cancer cell lines are expressed as
the median (range) of miRNA level relative to ER- breast cancer cell lines
Official Name ER− breast cancer cell lines (n = 19) ER+ breast cancer cell lines (n = 11) FC p-value
12 miRNAs up-regulated in ER+ compared to ER− breast tumors
miR-190b 1.0 (0.18-3.14) 42.9 (1.73-631) 42.99 <0.0001
miR-26a1 1.0 (0.36-3.22) 3.14 (0.36-7.83) 3.14 0.0477
miR-342-5p 1.0 (0.26-2.72) 8.24 (1.72-17.4) 8.24 <0.0001
miR-101-1 1.0 (0.50-2.54) 2.04 (0.61-6.64) 2.04 0.0111
let-7b 1.0 (0.34-4.92) 1.02 (0.01-5.24) 1.02 ns
miR-30e 1.0 (0.56-3.45) 1.50 (0.68-2.50) 1.50 ns
miR-30c2 1.0 (0.43-2.89) 0.92 (0.36-3.94) −1.09 ns
miR-143 1.0 (0.37-36.3) 1.22 (0.37-3.84) 1.22 ns
miR-26b 1.0 (0.41-4.89) 3.54 (0.98-7.81) 3.54 0.0006
miR-376c 1.0 (0.11-22.8) 0.92 (0.00-22.1) −1.09 ns
miR-193b 1.0 (0.26-3.90) 3.45 (0.29-12.0) 3.45 0.0052
let-7a 1.0 (0.50-2.01) 0.87 (0.10-3.61) −1.15 ns
8 miRNAs down-regulated in ER+ compared to ER− breast tumors
miR-18a 1.0 (0.15-2.39) 0.50 (0.24-25.1) −2.00 0.0642
miR-654-3p 1.0 (0.13-9.85) 0.46 (0.24-1.93) −2.17 ns
miR-18b 1.0 (0.17-2.45) 0.64 (0.16-27.5) −1.56 ns
miR-155 1.0 (0.00-72.2) 0.03 (0.00-0.84) −33.3 0.0609
miR-1244 1.0 (0.32-1.90) 0.91 (0.43-2.20) −1.10 ns
miR-203 1.0 (0.01-10.0) 5.62 (0.03-13.3) 5.62 0.0226
miR-92a1 1.0 (0.41-2.46) 0.62 (0.35-4.29) −1.61 0.0707
miR-146a 1.0 (0.03-91.6) 0.11 (0.03-0.25) −9.09 0.0583
The miRNAs are ranked according to the deregulation level between ER+ and ER− breast tumors. For each miRNA, we report the fold-change (FC) between ER+
and ER− breast cancer cell lines and the p-value associated to Mann–Whitney U test (ns for not significant)
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expression of miR-190b, miR-26a1, miR342-5p, miR-101-
1, miR-26b and miR-193b in ER+ breast cancer cell lines.
None down-regulation of miRNAs in ER+ compared to
ER- tumors was validated in cell lines; miR-203 was even
significantly up-regulated (p = 0.0226). It is worthy to note
that miR-190b, the highest up-regulated miRNA in ER+
tumors, was also the highest miRNA expressed in ER+
breast cancer cell lines, with a FC of 43 compared to 8 for
the second higher up-regulated miRNA, miR-342-5p
(Table 7), and that this up-regulation was observed in
most of ER+ breast cancer cell lines (Fig. 1) confirming
thus that miR-190b may have an important role in ER-
dependent tumorigenesis. This is why we decided to focus
next experiments on the expression and function of miR-
190b.
Confirmation of miR-190b up-regulation in ER+ compared
to ER− breast tumors
The heightened increase of miR-190b expression in ER+
compared to ER− breast tumors identified previously by
Qiagen quantitative RT-PCR was validated by another
experimental technique provided by Applied System
Biotechnologies. Indeed, on 20 breast tumor samples
which showed a FC of 23 between ER+ and ER− with
Qiagen technology, we found a similar increase of miR-
190b expression levels with Applied technology (FC of
26) (data not shown) and a strong positive correlation of
miR-190b expression between the two techniques
(Spearman’s coefficient correlation of 0.8977 significant
at p < 0.0001).
Prognostic value of miR-190b expression in breast cancer
patients
Using a Kaplan-Meier analysis, we showed that high ex-
pression of miR-190b did not impact metastasis-free sur-
vival in ER+ and ER- separated subgroups (datas not
shown). If we compared MFS according to the type of
treatment, we observed no prognostic impact related on
miR-190b expression level for patients who received
hormone therapy alone (p = 0.40, datas not shown). All
patients receiving other adjuvant treatment expressed
miR-190b at low level. Interestingly high expression of
miR-190b was associated with a prolonged metastasis-
free survival independently to ER status and treatment
(log rank test: p = 0.0173, HR = 1.869, 95 % CI = 1.12 to
3.13) (Fig. 2A), as well as a prolonged event-free sur-
vival (log rank test: p = 0.0046, HR = 2.048, 95 % CI =
1.248 to 3.360) (Fig. 2B). This result prompted us to ex-
plore functions of miR-190b in breast carcinogenesis.
Effect of estrogen on miR-190b expression
To identify if estrogen could explain the deregulation of
miR-190b between ER+ and ER− breast tumors, we mea-
sured its expression levels on the ERα-positive MCF-7
and T-47D breast cancer cell lines treated with 17β-
estradiol (E2). We did not observe an increase of miR-
190b expression levels in MCF-7 or in T-47D treated by
E2 whereas the expression of the well-known ERα-
induced gene pS2 was highly increased in the two cell
lines (Additional files 6: Figure S3A and S3B). Others 19
miRNAs did not respond to 17β-estradiol either (datas
not shown). Obviously we neither observed effect of
tamoxifen treatment on miR-190b expression in MCF-7
cell lines (datas not shown).
Role of miR-190b expression in tumor proliferation
The heightened increase of miR-190b in ER+ breast can-
cer prompted us to explore this possible biological sig-
nificance in cell proliferation. As initial step, the capacity
of proliferation induction was evaluated on breast cancer
cell lines ER+ MCF-7 and T-47D that were transfected
with an antagomir against miR-190b and on ER− MD-
MBA-231 that was transfected with a miR-190b mimic.
The efficacy of transfection was verified by quantifying
miR-190b in RNA extracted from transfected cells by
qRT-PCR (datas not shown). Antagomir did not affect
Fig. 1 Expression levels of miR-190b in breast cancer cell lines. Representation of miR-190b relative expression level in 30 breast cancer cell lines.
For each cell line, the miRNA levels were normalized such that the median value of the ER− breast cancer cell lines was 1 (horizontal line)
Cizeron-Clairac et al. BMC Cancer  (2015) 15:499 Page 10 of 14
proliferation of MCF-7 (Additional file 7: Figure S4A)
and T-47D cell lines (Additional file 7: Figure S4B) as
miR-190b mimic has no effect on MDA-MB-231 prolif-
eration (Additional file 7: Figure S4C). Other experi-
ments are therefore needed to decipher the role of miR-
190b in mammary tumorigenesis.
Discussion
From the study of more than 800 miRNA in ER+ en ER−
breast tumors and confirmation of our results in a large
validation series, we identified a robust collection of 20
miRNAs significantly deregulated in ER+ compared to
ER− breast cancers: 12 up-regulated and eight down-
regulated miRNAs. Among these 20 miRNAs, we found
ten miRNAs similarly deregulated in ER+ and ER−, inde-
pendently to their ER status: let-7a, let-7b, miR-26a1,
miR-101-1, miR-30c2, miR-143, miR-26b, miR-376c and
miR-92a1 which were down-regulated in both ER+/Nor-
mal and in ER−/Normal and miR-155 which was up-
regulated in both ER+/Normal and in ER−/Normal.
Moreover we found six miRNAs only deregulated in ER
+/Normal or in ER−/Normal (miR-30e, specifically down-
regulated in ER−, miR-342-5p, specifically up-regulated
in ER+, miR-18a, miR-18b and miR-654-3p, specifically
down-regulated in ER+ and miR-1244, specifically up-
regulated in ER−) and 3 miRNAs, not particularly at-
tractive since not deregulated in ER+/Normal nor in
ER−/Normal (miR-193b, miR-203 and miR-146a). In
contrast we found a very interesting miRNA, miR-
190b, which was not only the strongly up-regulated in
ER+ compared to ER− (FC of 23.30) but also the only
miRNA for which deregulation was different in breast
cancer according to ER status.
Production and maturation of miRNAs require a set of
proteins collectively known as the miRNA biogenesis
machinery and it is now established that alterations in
this machinery can generate changes in miRNA expres-
sion and contribute thus in the development and pro-
gression of cancer. We fully support the same view since
we found that several key miRNA processing genes are
differentially expressed between ER+ and ER− breast can-
cer, which may explain the different regulatory effects of
miRNAs in these two breast cancer subtypes. Indeed
DROSHA, DGCR8 and DICER1 were significantly down-
Fig. 2 Metastasis-free survival (a) and event-free survival (b) according to miR-190b expression level in breast tumors for the total cohort.
Kaplan-Meier survival analysis stratified by the miR-190b expression level. The p value was determined using the log rank test
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regulated in ER− whereas AGO2 was moderate up-
regulated. These results support previous observations
[16, 20, 32–34] and strengthen the pertinence of alter-
ations of the basic miRNA biogenesis machinery in
breast cancer.
For all six miRNAs located in intragenic regions, we
demonstrated a significant and positive correlation be-
tween expression of host gene and its resident
miRNA, in particular the well-known co-regulation of
the ER+ marker miR-342 and the ER-regulated gene
EVL [16, 35, 36]. However, in the study of Dvinge, re-
sults suggested a limited miRNA-host co-transcription
concerning only 49 out 227 same-strand intragenic
miRNAs [17].
These 20 miRNAs have been already described in early
studies identifying miRNAs implicated in breast cancers
[7, 9, 15, 17] but miR-190b retained our attention be-
cause it was the only miRNA strongly up-regulated in
ER+ compared to ER− breast tumors with a FC of 23
much higher than all other up-regulated miRNAs. This
observation remained true also in breast cancer cell lines
with a FC of 43 for miR-190b. Moreover miR-190b was
strongly up-regulated in ER+ breast tumors compared to
normal breast cancer and especially the only miRNA for
which deregulation was different according to ER sta-
tus. Indeed MiR-190b was significantly up-regulated in
ER+/Normal and down-regulated in ER−/Normal sug-
gesting a different deregulation of miR-190b depending
on the ER status. We could note that we did not select
miR-135b because of absence of expression in our
screening series whereas this microRNA would be dif-
ferentially expressed in ER+ and ER− breast tumors, and
is described by Aakula et al. as a regulator of ER [37]
Few studies reported miR-190b implication in cancers.
A recent next generation sequencing project identified
mir-190b among seven others microRNAs as a bio-
marker for the diagnosis of Merkel cell carcinoma [38].
In lung cancer, miR-190b could be detected easily in
serum of patients to facilitate diagnosis [39]. MicroRNA
expression profile associated with response to neoadju-
vant chemoradiotherapy in locally advanced rectal can-
cer patients included miR-190b [40]. However none of
these studies explored mechanism of action of miR-190b
and its targets did not have been well described contrary
to miR-190 that could interfere with VEGF-mediated
angiogenesis [41]. Morevover miR-190b has not been se-
lected by previous microarray breast cancer studies [16,
17, 19, 42] so we tried to decipher its properties in
breast cancer. By treating MCF7 and T47D cell lines
with estradiol, we demonstrated that miR-190b is not
directly regulated by this hormone whereas it seems par-
ticularly deregulated in ER+ breast tumors. We could
speculate that expression of miR-190b is controlled by
other mechanisms like ER-signaling pathways independent
of estrogen but it remains to be demonstrated [43, 44].
Transfection experiments with anti-miR-190b in MCF7
and T47D cell lines, or with mimic of miR-190b in MDA-
MB-231 cell line have shown that miR-190b has probably
no effect on cell proliferation. Nevertheless, if the mecha-
nisms of its expression regulation like its exact role in
oncogenesis of ER+ breast cancers are elucidated, miR-
190b could become a very interesting biomarker in ER+
breast cancers as it has the advantage to be highly
expressed in this subtype and therefore easy to detect by
RT-qPCR. We could speculate that miR-190b would be
used as a circulating biomarker for minimal residual dis-
ease follow-up in hormone-dependent breast cancers to
detect therapeutic resistance and early relapses.
Last but not least, a high expression of miR-190b was
associated with a prolonged MFS and EFS in breast tu-
mors, independently to ER status. To date miR-190b just
appears in one study using global microRNA expression
profiling to identify markers of recurrence in ER+ pa-
tients receiving tamoxifen [45]. Ten highly significant
miRNAs including miR-190b could discriminate the pa-
tient samples according to outcome but this result was
not confirmed in two validation cohorts. More interest-
ing, miR-190b and its function have been explored in a
very recent study in human hepatocellular carcinoma
[46]. The authors have showed that up-regulation of
miR-190b could play a role for decreased IGF-1 that in-
duce insulin resistance in hepatocellular carcinoma.
IGF-1 appears to be a direct target of miR-190b and an-
other study have demonstrated that IGF-1 and ER ex-
pressions are raised in breast cancer cases which were
likely to develop tamoxifen resistance [47]. Taking into
account our present work and these two recent studies,
we argued that the link between miR-190b and tamoxi-
fen resistance could be very interesting to study in breast
cancers.
Conclusion
This study identified miR-190b as the highest up-
regulated miRNA in ER+ breast cancers compared to
ER− tumors and to normal breast tissues. Surprisingly,
expression of miR-190b is not directly regulated by es-
tradiol. Using synthetic miRNA to mimic or to
antagonize miR-190b, we demonstrated that miR-190b
does not affect the proliferation of transfected breast
cancer cell lines. However miR-190b affects MFS of
breast cancer patients. Even if miR-190b exact role in
breast carcinogenesis and regulation expression mecha-
nisms remain to elucidate, this microRNA seems to be
specifically expressed in ER+ breast cancers at higher
level that all others miRNAs and could therefore repre-
sent a new biomarker of interest for the follow-up of
this subtype of tumors.
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Additional files
Additional file 1: Table S1. Relative mRNA expression level of 804
miRNAs studied in normal, ER+ and ER- breast tissues. For each miRNA,
we give the number of samples analyzed (Nb), the median and the range
(min and max) of mRNA level relative to normal breast tissue samples,
the median of cycle threshold (Ct) obtained by RT-qPCR, the fold
change (FC) between ER+ and ER- tumors and the p-value associated to
Mann-Whitney's test (ns for not significant when p-value >0,05). The
miRNAs are alphabetically ranked.
Additional file 2: Table S2. Relative mRNA expression level of 333
informative miRNAs in normal, ER+ and ER- breast tissues. For each
miRNA, we give the number of samples analyzed (Nb), the median and
the range (min and max) of mRNA level relative to normal breast tissue
samples, the median of cycle threshold (Ct) obtained by RT-qPCR, the fold
change (FC) between ER+ and ER- tumors and the p-value associated to
Mann-Whitney's test (ns for not significant when p-value > 0,05). All miRNAs
indicated with an asterisk following their name, all miRNAs with a median
of values of cycle threshold (Ct) obtained by RT-qPCR upper to 30 in the
three groups and all miRNAS with a Ct upper to 30 in at least 60 % of
samples were filtrered. The miRNAs are alphabetically ranked.
Additional file 3: Figure S1. Expression profiles of 12 miRNAs significantly
up-regulated in ER+ compared to ER− breast tumors. Five expression profiles
were identified: miR-26a1 expression representative of let-7b, miR-101-1,
miR-30c2, miR-143, miR-26b, miR-376c and let-7a1 in A, miR-30e expression
in B, miR-193b expression in C, miR-342-5p expression in D and miR-190b
expression in E. For each time, the mRNA levels were normalized such that
the median value of normal cells was of 1 (mean ± SEM, n = 3). Only the
p values analyzing the differences in miRNA expression between ER+ and
normal breast tissue and between ER− and normal breast tissue by the
Mann-Whitney’s test are given.
Additional file 4: Figure S2. Expression profiles of 8 miRNAs significantly
down-regulated in ER+ compared to ER− breast tumors. Five expression
profiles were identified: miR-654-3p expression representative of miR-18b
and miR-18a expression in A, miR-146a expression representative of miR-203
in B, miR-92a1 expression in C, miR-155 expression in D and miR-1244
expression in E. For each time, the mRNA levels were normalized such that
the median value of normal cells was of 1 (mean ± SEM, n = 3). Only the
p values obtained by the Mann-Whitney’s test analyzing the differences in
miRNA expression between ER+ and normal breast tissue and between
ER- and normal breast tissue are given.
Additional file 5: Table S3. Relative miRNA expression levels of the 30
selected miRNAs in breast cancer. Results in breast tumors are expressed
as the median (range) of miRNA level relative to normal breast tissues.
For each miRNA, we report the fold-change (FC) between breast tumors
and normal breast tissue and the p-value associated to Mann–Whitney
test (ns for not significant). These 30 miRNAs are ranked according their
expression level in ER+ compared to ER- breast tumors (Table 3).
Additional file 6: Figure S3. Effects of estradiol on expression levels of
miR-190b and pS2 in MCF-7 (A) and T-47D (B). Cell lines were treated with
estradiol (E2) or vehicle during the indicated time and mRNA levels were
measured by RQ-PCR normalized to RNU44 (mean ± SEM, n = 3). For each
time, the mRNA levels were normalized such that the median value of
control cells was of one (horizontal line).
Additional file 7: Figure S4. MiR-190b does not interfere with proliferation
in MCF7, T47D and MDA-Mb-231 cell lines. MCF7 (A) and T-47D (B) cell lines
were transfected with antagomir against miR-190b whereas MDA-MB-231 cell
line (C) was transfected with miR-190b mimic. Cytotoxicity was evaluated by
MTT colorimetric test at indicated times (mean ± SEM, n = 3).
Abbreviations
Ct: Cycle threshold; EFS: Event free survival; ER: Estrogen receptor; FC: Fold
change; MFS: Metastasis free survival; RT-qPCR: Reverse transcriptase
quantitative polymerase chain reaction; RT-PCR: Reverse transcriptase
polymerase chain reaction.
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